Albert Bourla Net worth 2022
Albert Bourla Net worth 2022 – Pfizer CEO Albert Bourla has an approximate net worth of more than $30 million. He has been in the Pharma company since 1993.
|Net Worth||$30 Million|
|Date of Birth||21 October 1961|
|Age||61 Years (2022)|
Albert Bourla Biography
Albert Bourla is the chairman and chief executive officer of Pfizer, an American pharmaceutical business. He is a Greek-American veterinarian. He joined Pfizer in 1993 and has held various executive positions across the company’s divisions. Bourla held the position of chief operating officer prior to becoming CEO.
He serves or has served on the boards of the Biotechnology Innovation Organization, Catalyst, the Partnership for New York City, and the Pharmaceutical Research and Manufacturers of America, in addition to Pfizer and the Pfizer Foundation. Bourla also belongs to the Business Roundtable and The Business Council. He interacts with corporate executives such as Bill Gates on a regular basis.
Bourla is credited with restructuring Pfizer into a corporation focused on research and development and branded patent-protected prescription pharmaceuticals, thanks to his early passion of animals and medicine.
He is also credited for helping to develop Improvac, a vaccination that eliminates boar taint, as well as reorganizing Pfizer’s vaccine division to focus on staphylococcus, clostridioides difficile infection, baby illnesses, and the Pfizer–BioNTech COVID-19 vaccine. He opposes government intervention in pharmaceutical pricing, which he argues will stifle investment in future medicine development.
Albert Bourla Wife and Children
Bourla lives in Scarsdale, New York, with his wife. He is the father of two children, a son and a daughter. In 2020, Pfizer paid him $21 million in compensation.
Albert Bourla Background
Bourla was born and reared in the Greek city of Thessaloniki. His Sephardi Jewish parents were among the 2,000 Jews in Thessaloniki who survived the Holocaust.
Bourla claims that his mother was minutes away from being shot by a firing squad when she was saved by a ransom paid to a Nazi Party official by her non-Jewish brother-in-law, and that his father was out of the Jewish ghetto when the residents were taken to Auschwitz concentration camp and went into hiding, never to see his parents again.
Albert Bourla Education
Bourla graduated from the Veterinary School of Aristotle University of Thessaloniki with a doctorate in reproductive biotechnology in 1985.
He and his wife left Greece when he was 34 after a promotion at Pfizer, and he has lived in seven different locations in four different nations since then.
Albert Bourla Career
Bourla began his career with Pfizer in 1993 as a veterinary medicine doctor and technical director for the company’s animal health division in Greece.
He arrived in the United States in 2001.
He held various management positions at Pfizer’s Zoetis (formerly known as Animal Health) and other subsidiaries.
He was the region president for Animal Health’s Europe, Africa, and Middle East division from 2005 to 2009. He was in charge of the Europe, Africa, and Asia Pacific division between 2009 and 2010. He oversaw the merging of Wyeth’s Fort Dodge Animal Health division with Pfizer in these territories in the latter role.
Bourla was president and general manager of Pfizer’s Established Products Business Unit from 2010 to 2013.
He developed a business there for the company’s medications, which had recently lost their patent exclusivity.
Bourla was Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business from January 2014 to January 2016, where he oversaw the company’s work on cancer and heart drugs, among other things, and helped launch Eliquis, an anticoagulant, and Ibrance, a breast cancer treatment drug.
He was the group president of Pfizer Innovative Health from February 2016 to December 2017. Innovative Health’s revenue climbed by 11% in 2016 under his tenure.
On January 1, 2018, Bourla took over as Pfizer’s chief operational officer (COO), supervising the company’s medication development, manufacturing, sales, and strategy.
During his time as COO, he restructured Pfizer and split off the consumer health care division.